Samsung Biologics adds new manufacturing plant

By The Science Advisory Board staff writers

August 11, 2020 -- Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and manufacturing capabilities, in part due to COVID-19.

In total the company plans to invest over $2 billion in the two facilities, which will add 256-kiloliter capacity and begin manufacturing activities in the second half of 2022. The site will be the world's largest manufacturing facility at a single location. The plant will incorporate multiscale manufacturing by incorporating advantages from Samsung's three previous sites.

The 23.8 million sq m facility will incorporate real-time production schedule simulation with automation and the latest biomanufacturing technologies and utility supply-based optimization. The new site will contain streamlined application, smart disposal of high-concentration wastewater, and improvement of nitric acid emissions.

The company is also in negotiations with the authorities at the Incheon Free Economic Zone to purchase additional land for a second complex. This site is located near the company's current complex and will add 330,000 sq m of manufacturing space.

Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Copyright © 2020 scienceboard.net


Conferences
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter